Glucuronidation

Glucuronidation is a conjugation reaction — one of the body's main Phase II metabolic pathways — in which an enzyme attaches glucuronic acid to a foreign compound, tagging it for excretion. The enzyme family responsible, UDP-glucuronosyltransferases (UGTs), is concentrated in the liver but is also active in the intestines, kidneys, and, to a lesser degree, the brain.

Phase II metabolism generally follows Phase I (oxidation, reduction, hydrolysis), but glucuronidation can also act directly on drugs that already carry the right functional groups — hydroxyl, carboxyl, amino, or thiol. The result is a glucuronide conjugate: typically larger, more water-soluble, and biologically inert.

Because the glucuronide product is usually inactive, the route is often framed as a termination step. That framing is mostly accurate, but there are important exceptions — a compound can produce a glucuronide that retains pharmacological activity, or is even more potent than the parent drug.

How it works · its role

UGT enzymes transfer glucuronic acid from a co-factor (UDP-glucuronic acid, derived from glucose) onto the target molecule. The attachment point is almost always a nucleophilic atom — an oxygen, nitrogen, or sulfur — that the enzyme can reach on the substrate's surface.

Once conjugated, the glucuronide typically carries a negative charge at physiological pH, which blocks it from crossing cell membranes easily. Smaller glucuronides are filtered by the kidneys and leave in urine; larger ones are secreted into bile and can be cleaved back to the parent compound by gut bacteria — a recycling loop called enterohepatic recirculation that can extend a drug's effective duration.

UGT activity varies substantially between individuals because of genetic differences across the UGT gene family. Some people glucuronidate specific compounds much faster or slower than average, producing meaningful differences in both duration of effect and metabolite accumulation.

Relevance to substances & effects

Several substance classes are cleared primarily by glucuronidation. Among benzodiazepines, oxazepam, lorazepam, and temazepam bypass Phase I entirely — a clinically significant fact because their metabolism is less sensitive to liver impairment and less prone to interactions driven by Phase I enzymes such as CYP3A4.

Opioids illustrate how glucuronidation does not always inactivate its substrates. Morphine is glucuronidated to two products: morphine-6-glucuronide, a potent opioid agonist thought to contribute substantially to morphine's analgesic effect, and morphine-3-glucuronide, which is inactive at opioid receptors but is associated with neuroexcitatory effects at high concentrations.

Cannabis metabolites — particularly THC-COOH, the main product of THC oxidation — are glucuronidated before excretion in urine. This conjugate is the target of standard urine immunoassay drug tests.

Because THC-COOH accumulates in fat tissue before being slowly released and glucuronidated, detection windows in urine are substantially longer than the duration of cannabis's subjective effects — a mismatch that can mislead both users and clinicians when interpreting a positive result.